NEW YORK – September 20, 2017 – Informa Pharma Intelligence, the leading healthcare and pharmaceutical data and analysis firm today released its “Deep Dive: Depression Drug Development” report, detailing the future growth of the US depression drug market. Findings reveal the market is expected to grow from $4.6 billion in 2015 to $7.3 billion in 2024, driven primarily by pipeline drugs from new therapeutic classes including N-methyl D-aspartate (NMDA) receptor-targeting products esketamine (Johnson & Johnson) and rapastinel (Allegran),as well as opioid-based ALKS 5461 (Alkermes).
The new drug classes are going to upend the overall market, which is widely reliant on sales of two traditional antidepressant classes – the selective serotonin re uptake inhibitor (SSRI) andserotonin-norepinephrine re uptake inhibitor (SNRI) antidepressants. Overall growth of the depression pharmaceutical market is contingent on the approval, sales and success of esketamine, rapastinel, and ALKS 5461. By 2024, the combined forecast sales of these new drugs will total $4.15 billion, which is greater than the absolute $2.7 billion increase in the wider depression market.
There are inherently high risks associated with each of the new drugs, which may affect their approval and sale. Esketamine possess similar dissociative effects to the popular recreational drug Ketamine and ALKS 5461 is an opioid-based drug formulation, making both high risk for abuse and addiction, likely placing stricter rules on their release and use. Michael Hay, Head of Intelligence Products for Informa Pharma Intelligence said “Should the US Food and Drug Administration (FDA) approve esketamine it’ll be game changing for the depression pharmaceutical market. It represents a new therapeutic class for depression – rapid onset – which many patients need. At the same time esketamine is similar to Ketamine, and has high potential for abuse. Similarly, in clinical trials, ALKS 5461 has shown significant potential for helping treatment-resistant patients, but the opioid active ingredient in the drug may create undesirable side effects, including abuse and addiction.
As the FDA and others work to curb drug abuse in the US, both esketamine and ALKS 5461 will be greatly debated and scrutinized.”Charting the Future of Key Depression Drugs Overtime, familiar, brand name drugs in the two traditional antidepressant classes SSRI and SNRI are going to lose their market share. While this will mostly be due to generic versions entering the market as patents expire, the addition of new drug classes such as esketamine that provide rapid-onset relief for patients will take market share.Below are the current top-selling depression drugs in the US market and sales outlooks for each, which are all expected to decrease in sales by 2024:
Pending approval, which is expected based on positive clinical trial efficacy results and strong safety signals , ALKS 5461, esketamine and rapastinel are all expected to greatly increase their sales by 2024, owning a high portion of the depression drug market:
Professional Perspectives Informa Pharma Intelligence’s Datamonitor Healthcare surveyed 238 primary care physicians and psychiatrists in the US, Japan, and five major EU markets (France, Germany, Italy, Spain,and the UK) treating patients with depression in November 2015, to highlight the real-world implications of the pharmaceutical depression market. Findings show:
If you’d like access to the full report from Informa Pharma or additional information on the depression pharmaceutical market, please reach out to InformaPharma@Diffusionpr.com. About Informa Pharma Intelligence Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo –to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth. With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease,clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. Informa Pharma Intelligence, is part of the wider Informa Business Intelligence brand that provides insight into six core industries - Pharma & Healthcare; Agribusiness & Commodities;Finance; Telecoms, Media & Technology; Maritime & Law; Infrastructure. For more information visit pharmaintelligence.informa.com. For more information, please contact:Allie Tedone/Danielle CecchiniDiffusion PR+1 646-571- 0120 email@example.com
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: